ÌìÏÂÉúÃü¿ÆÑ§Ç°Ñض¯Ì¬Öܱ¨£¨ÈýÊ®¶þ£©
£¨11.15 -- 11.21 / 2010£©
Ò»¾º¼¼¹ú¼Ê¼¯ÍÅ:ÌÕ¹úÐÂ
¡¡¡¡±¾Öܶ¯Ì¬°üÀ¨ÒÔÏÂÄÚÈÝ£ºÐþÉ«ËØÁöÓëÖ×Áö¸Éϸ°ûÄ£×Ó²»·û£»¿ÆÑ§¼ÒÑÐÖÆ³öÐÂÐÍϸ°û×÷Óýϵͳ£»Ñо¿Õ¹ÏÖmiRNAÔÚÏÈÌìÃâÒßÖÐ×÷Óã»Ñо¿Õ¹ÏÖ·ÎÑ×ѬȾÈËÌå·´Ó¦»úÖÆ£»FTO»ùÒòÌ«¹ý»îÔ¾¿Éµ¼Ö·ÊÅÖ£»Î¬ÉúËØDȱ·¦¿Éµ¼Ö°×Ѫ²¡¶ñ»¯¡£
1. ÐþÉ«ËØÁöÓëÖ×Áö¸Éϸ°ûÄ£×Ó²»·û
¡¾ÕªÒª¡¿ScienceDaily (Nov. 15, 2010)
¡¡¡¡ÃÀ¹úMichigan´óѧµÄÑо¿Ö°Ô±·¢Ã÷´ó´ó¶¼ÀàÐ͵ÄÐþÉ«ËØÁöϸ°û¶¼ÄÜÐγɶñÐÔÖ×Áö£¬ÎªÐþÉ«ËØÁöÕâÒ»×îÖÂÃüµÄƤ·ô°©²»ÇкÏÔ½À´Ô½Ê¢ÐеÄÖ×Áö¸Éϸ°ûÄ£×ÓÌṩÁËÐÂÖ¤¾Ý¡£ÁíÍ⣬Ñо¿Ö°Ô±»¹·¢Ã÷ÐþÉ«ËØÁöϸ°ûÄÜͨ¹ý¿ª¹Ø²î±ðµÄ»ùÒò¸Ä±ä×ÔÌå̬״¶ø³ÉΪÉñÃØµÄ±äÐÎÕßÀ´ÌÓ±ÜÖÎÁÆ¡£
¡¾µãÆÀ¡¿
¡¡¡¡¸Ã·¢Ã÷×÷Ϊһ¸ö·´Ö¤Åú×¢°©Ö¢±¬·¢µÄÖ×Áö¸Éϸ°ûÄ£×Ó¿ÉÄÜÊǹýʧµÄ£¬°©Ö¢µÄÒòÓÉÒÀÈ»ÓдýÆÊÎö¡£
¡¾ÔÎÄժ¼¡¿Cancer Cell, 2010; 18 (5): 510-523 DOI: 10.1016/j.ccr.2010.10.012
Phenotypic Heterogeneity among Tumorigenic Melanoma Cells from Patients that Is Reversible and Not Hierarchically Organized.
Elsa Quintana, Mark Shackleton, Hannah R. Foster, et al.
We investigated whether melanoma is hierarchically organized into phenotypically distinct subpopulations of tumorigenic and nontumorigenic cells or whether most melanoma cells retain tumorigenic capacity, irrespective of their phenotype. We found 28% of single melanoma cells obtained directly from patients formed tumors in NOD/SCID IL2Rnull mice. All stage II, III, and IV melanomas obtained directly from patients had common tumorigenic cells. All tumorigenic cells appeared to have unlimited tumorigenic capacity on serial transplantation. We were unable to find any large subpopulation of melanoma cells that lacked tumorigenic potential. None of 22 heterogeneously expressed markers, including CD271 and ABCB5, enriched tumorigenic cells. Some melanomas metastasized in mice, irrespective of whether they arose from CD271 or CD271+ cells. Many markers appeared to be reversibly expressed by tumorigenic melanoma cells.
2. ¿ÆÑ§¼ÒÑÐÖÆ³öÐÂÐÍϸ°û×÷Óýϵͳ
¡¾ÕªÒª¡¿
¡¡¡¡ÃÀ¹úÍþ˹¿µÐÁ´óѧÂóµÏÑ··ÖУµÄ¿ÆÑ§¼ÒÃÇ¿ËÈÕ¿ª·¢³öÒ»Ì×ÐÂϸ°û×÷Óýϵͳ£¬ÓÐÍûΪϸ°ûÖÎÁÆÌṩԽ·¢Ò»ÖºÍÇå¾²µÄϸ°û×÷ÓýÎï¡£11ÔÂ14Èյġ¶×ÔÈ»¡ªÒªÁìѧ¡·¿¯µÇÁËÕâһЧ¹û¡£Ïòµ¼ÕâÏîÑо¿µÄLaura Kiessling½ÌÊÚÌåÏÖÕâÌ×ϵͳ²¢²»Ìڹ󣬿ɼ縺¶àÄÜϸ°û×÷ÓýÖеĴó×ÚÔ¤¹ÀÊÂÇé¡£ÕâÏîÊÖÒÕ¡°ºÜ¼òÆÓ¡±£¬¡°ÈκÎÈ˶¼ÄÜʹÓᱡ£ÏÖÔÚ£¬´ó²¿·ÖÈËÀàÅßÌ¥¸Éϸ°ûµÄ×÷Óý¶¼ÊÇ×÷ΪʵÑéÊÒÑо¿ÓÃ;µÄ£¬¶øÍ¨³£Ëù½ÓÄɵÄ×÷ÓýÒªÁìÓÖÈÝÒ×Ôì³ÉÖÖÖÖÎÛȾ¡£ÕâÌ×ÐÂϵͳ½ÓÄÉÒ»ÖÖ»¯Ñ§ºÏ³ÉÖÆµÃµÄ¿ÉÓë¸Éϸ°ûÏàÍŽáµÄÂÑ°×Æ¬¶Ïµ×Î²¢Í¨¹ýÓëÌØ¶¨×÷Óý»ùÍŽᣬ¿É½«Ï¸°û×÷ÓýÀο¿ÔÚδ·Ö½â½×¶Î´ïÈý¸öÔ»òÕ߸ü³¤Ê±¼ä¡£¾Ý±¨¸æÏÔʾ£¬¸ÃϵͳÒà¿ÉÓÃÓÚÓÕµ¼¶à¹¦Ð§¸Éϸ°û×÷Óý¡£¡°¿ÆÑ§¼ÒÏÖÔÚÆÕ±é½ÓÄɵÄ×÷Óýϵͳ¶¼ÓÐ×Å·ÇÌØ¶¨µÄÈõµã£¬²¢ÇÒȱ·¦Ò»ÖÂÐÔ£¬ÒÔÖ·ºÆðÖÊÁ¿²î±ð¡±£¬ Ïòµ¼ÕâÏîÑо¿µÄLaura Kiessling½ÌÊÚÚ¹ÊÍ£¬¡°ÎÒÃÇÑз¢µÄÕâÌ×ÏµÍ³ÌØ¶¨ÐԺܺ㬲¢ÇÒ²¢²»¹ó¡±¡££¨¿ÆÑ§Íø ÕÅЦ/±àÒ룩
¡¾µãÆÀ¡¿
Ô½·¢Ò»Ö¡¢Îȹ̺ÍÇå¾²µÄϸ°û×÷ÓýÎï¹ØÓÚ¸Éϸ°û×÷ÓýºÍÑо¿µÄÖÊÁ¿¿ØÖÆ´óÓÐÀûÒæ¡£ÕâÒ»ÊÖÒÕ¿ÉÄÜ»áÔö½ø¸Éϸ°ûÑо¿ÁìÓòµÄÉú³¤¡£
¡¾ÔÎÄժ¼¡¿Nature Methods, 14 November 2010 DOI: 10.1038/nmeth.1532
A defined glycosaminoglycan-binding substratum for human pluripotent stem cells
Joseph R Klim, Lingyin Li, Paul J Wrighton, et al.
To exploit the full potential of human pluripotent stem cells for regenerative medicine, developmental biology and drug discovery, defined culture conditions are needed. Media of known composition that maintain human embryonic stem (hES) cells have been developed, but finding chemically defined, robust substrata has proven difficult. We used an array of self-assembled monolayers to identify peptide surfaces that sustain pluripotent stem cell self-renewal. The effective substrates displayed heparin-binding peptides, which can interact with cell-surface glycosaminoglycans and could be used with a defined medium to culture hES cells for more than 3 months. The resulting cells maintained a normal karyotype and had high levels of pluripotency markers. The peptides supported growth of eight pluripotent cell lines on a variety of scaffolds. Our results indicate that synthetic substrates that recognize cell-surface glycans can facilitate the long-term culture of pluripotent stem cells.
3. Ñо¿Õ¹ÏÖmiRNAÔÚÏÈÌìÃâÒßÖÐ×÷ÓÃ
¡¾ÕªÒª¡¿
¡¡¡¡11ÔÂ10ÈÕ£¬¹ú¼ÊȨÍþѧÊõÆÚ¿¯¡¶ÃâÒßѧÆÚ¿¯¡·£¨Journal of Immunology£©ÔÚÏß½ÒÏþÁËÖпÆÔºÉϺ£°Í˹µÂËù×îÐÂÑо¿Ð§¹û£¬¸ÃЧ¹ûÕ¹ÏÖÁËmicroRNAÔÚÏÈÌìÃâÒßÖеÄ×÷ÓÃÒÔ¼°µ÷¿Ø»úÖÆ£¬²¢Ñо¿ÁËÕâÖÖ×÷ÓÃÔÚµØÈûÃ×ËÉ¿¹Ñ×֢ЧӦÖеÄְλ¡£ÕâÏîЧ¹ûÊDz©Ê¿Ñо¿ÉúÖìÇåÔ´Ôڸ걦ѧÑо¿Ô±Ö¸µ¼ÏÂÍê³ÉµÄ¡£ÏÈÌìÃâÒßÖÐÑ×Ö¢Òò×ӵĵ÷ÀíÐèÒª±»Ï¸Ä嵨¿ØÖÆ£¬¹ý¶à»òÕß¹ýÉÙµÄÑ×Ö¢Òò×Ó¶¼¿ÉÄÜ»áÔì³É»úÌåµÄ¸ºÃæ·´Ó¦¡£MAPKÊÇÈÏÕæÑ×Ö¢Òò×Ó±¬·¢µÄÖ÷ÒªÐźÅͨ·£¬¿ÉÒÔÔÚTLR¼¤»îµÄÃâÒß·´Ó¦ÖÐͨ¹ýÁ×ËữÀ´ÓÕµ¼ÏÂÓÎת¼Òò×Ó¼¤»îÑ×Ö¢Òò×Óת¼¡£¶øÍ¬Ê±£¬Õâ¸öÐźÅͨ·µÄ¼¤»î»áµ¼ÖÂMKP-1µÄ±¬·¢£¬ÕâÊÇÒ»ÖÖ¿ÉÒÔͨ¹ý¶ÔMAPK¾ÙÐÐÈ¥Á×Ëữ×÷ÓÃʹÑ×Ö¢·´Ó¦Ïµ÷µÄ·Ö×Ó¡£MAPKÓëMKP-1×é³ÉÁËÒ»¸ö±ê×¼µÄ¸º·´Ïìµ÷Àí¾¥»·½á¹¹¡£
¡¡¡¡Ñо¿Ö°Ô±·¢Ã÷Ò»ÖÖmicroRNA (miR-101)¿ÉÒÔͨ¹ý°ÐÏòMKP-1 mRNAµÄ3¡¯- UTRÀ´µ÷ÀíMAPKµÄ·´Ó¦£¬½ø¶øÓ°ÏìÏÂÓÎÑ×Ö¢Òò×ÓµÄÉøÍ¸¡£¸ü½øÒ»²½µÄʵÑéÅú×¢£¬PI3K/AKTͨ·¿ÉÒÔµ÷¿ØmiR-101µÄ±í´ï£¬´Ó¶øÓ°ÏìMKP-1ÒÔ¼°MAPKµÄ±í´ïºÍ»î»¯ÇéÐΣ¬ÕâÌåÏÖP3IK/AKTͨ·¿ÉÒÔͨ¹ýmiR-101ÓëMAPKͨ·¾ÙÐд®ÈÅ¡£Ñо¿·¢Ã÷£¬ÔÚµØÈûÃ×ËɵĿ¹Ñ×Ö¢×÷ÓÃÖУ¬miR-101±»ÒÖÖÆ£¬ÖÁÉÙ²¿·ÖÊÇÓÉÓÚµØÈûÃ×Ëɵ¼ÖÂMKP-1´ó·ù¶ÈÉϵ÷¶ø½µµÍÁËMAPK»î»¯×÷Óá£ÕâÏîÑо¿ÎªÒÔºó¶Ôϸ°ûÒò×ÓÉøÍ¸ÒýÆðµÄÃâÒß¼²²¡µÄÖÎÁÆÕ½ÂÔÌṩÁËеİбꡣ´ËÏîÑо¿»ñµÃ¿Æ¼¼²¿¡¢¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð¡¢ÉϺ£ÊпÆÑ§ÊÖÒÕίԱ»áºÍÖйú¿ÆÑ§ÔºµÄ×ʽð×ÊÖú£¬²¢ÒѾÉêÇëÁËÏà¹Ø×¨Àû¡££¨ÈªÔ´£ºÖпÆÔºÉϺ£°Í˹µÂËù£©
¡¾µãÆÀ¡¿
¡¡¡¡Î¢ºËÌǺËËámiR-101 ͨ¹ý×÷ÓÃÓÚʹÑ×Ö¢·´Ó¦Ïµ÷µÄMKP-1ÐźÅͨ·µ÷Àí¾ÞÊÉϸ°û¶Ôϸ¾úÖ¬¶àÌǵÄÏÈÌìÃâÒß·´Ó¦¡£¸Ã·¢Ã÷¸»ºñÁËÑ×Ö¢ÓëÃâÒß·´Ó¦µÄ»úÀíÉϵÄÊìϤ£¬ÓÐÖúÓÚ¿ª·¢ÐµĿ¹Ñ×ÒªÁì¡£
¡¾ÔÎÄժ¼¡¿The Journal of Immunology, 2010, doi:10.4049/jimmunol.1000798
MicroRNA-101 Targets MAPK Phosphatase-1 To Regulate the Activation of MAPKs in Macrophages
Qing-Yuan Zhu, Qin Liu, Jian-Xia Chen, et al.
MAPK phosphatase-1 (MKP-1) is an archetypical member of the dual-specificity phosphatase family that deactivates MAPKs. Induction of MKP-1 has been implicated in attenuating the LPS- or peptidoglycan-induced biosynthesis of proinflammatory cytokines, but the role of noncoding RNA in the expression of the MKP-1 is still poorly understood. In this study, we show that MKP-1 is a direct target of microRNA-101 (miR-101). Transfection of miR-101 attenuates induction of MKP-1 by LPS as well as prolonged activation of p38 and JNK/stress-activated protein kinase, whereas inhibition of miR-101 enhances the expression of MKP-1 and shortens p38 and JNK activation. We also found that expression of miR-101 is induced by multiple TLR ligands, including LPS, peptidoglycan, or polyinosinic-polycytidylic acid, and that inhibition of PI3K/Akt by LY294002 or Akt RNA interference blocks the induction of miR-101 by LPS in RAW264.7 macrophage cells. Moreover, treatment of cells with dexamethasone, a widely used anti-inflammatory agent, markedly inhibits miR-101 expression and enhances the expression of MKP-1 in LPS-stimulated macrophages. Together, these results indicate that miR-101 regulates the innate immune responses of macrophages to LPS through targeting MKP-1.
4. Ñо¿Õ¹ÏÖ·ÎÑ×ѬȾÈËÌå·´Ó¦»úÖÆ
¡¾ÕªÒª¡¿
¡¡¡¡¾ÝÓ¢¹ú¡¶ÖðÈÕµçѶ±¨¡·±¨µÀ£¬Ó¢¹ú¿ÆÑ§¼ÒÐû²¼£¬ËûÃÇ·¢Ã÷ÁËÉíÌå×ÔÈ»¶Ô¿¹Òý·¢·ÎÑ׺ÍÄÔĤÑ׵ķÎÑ×Á´Çò¾úµÄз½·¨£¬³¯ÑÐÖÆ³öÖÎÁÆ·ÎÑ׺ÍÄÔĤÑ×µÄͨÓÃÐÍÒßÃçÓÖǰ½øÁËÒ»´ó²½¡£¸ÃÑо¿½ÒÏþÔÚÃÀ¹ú¡¶¿ÆÑ§¹«¹²Í¼Êé¹Ý¡ª²¡ÔÌå¡·ÔÓÖ¾ÉÏ¡£Ó¢¹úÀ³Ë¹ÌØ´óѧºÍ¶¼°ØÁÖÊ¥ÈýһѧԺµÄÑо¿Ö°Ô±ÔÚÂÛÎÄÖÐÒÔ¡¶Ã÷È·ÉϵÄÖØ´óÍ»ÆÆ¡·ÎªÌ⣬չÏÖÁËÃâÒßϵͳÔõÑù¶Ô·ÎÑ×Á´Çò¾úÒý·¢µÄѬȾ×÷³ö·´Ó¦µÄ»úÖÆ¡£Ñо¿Ö°Ô±³Æ£¬ËûÃÇÊ״η¢Ã÷£¬·ÎÑ׻ᴥ·¢Ò»ÈºÃû½ÐÑ×ÐÔÌåµÄÃâÒßϵͳÂѰס£µ±±»Òý·¢Ê±£¬Ñ×ÐÔÌå»áÆô¶¯Ò»ÏµÁÐÊÂÎñ£¬µ¼Ö°üÀ¨°×½éËØÔÚÄڵĻîÐÔ·Ö×ÓµÄÌìÉúÒÔ¶Ô¿¹Ñ¬È¾¡£¿ÆÑ§¼Ò¿ÉÒԾݴËÑз¢³öÐÂÒ©ÎÕâЩҩÎïÄÜ´¥·¢Í¬ÑùµÄ·´Ó¦£¬½«¼²²¡Ä¨É±ÔÚÃÈѿ״̬¡£À³Ë¹ÌØ´óѧµÄ°¢À˹¡¤¿¨µÏ¸ñ³ºÍÊ¥ÈýһѧԺµÄ°¬µÂ¡¤À¸¥ÀÕÒÔΪ£¬ÕâÒ»¹ØÓÚ¶¾ËØÔõÑùͬÃâÒßϵͳÍŽáµÄÐÂÈÏÖªÒâζ×ÅÑо¿Ö°Ô±¿ÉÒÔÑз¢³öÐÂÒßÃç¡£ÏÖÔÚ£¬¶Ô¿¹·ÎÑ×Á´Çò¾úµÄÒßÃç¿ÉÒÔ·ÀÓù7ÖÖ²î±ðµÄ¾úÖ꣬µ«ÐÂÒªÁìÑз¢³öµÄÒßÃçÓ¦¸ÃÄܹ»¶Ô¿¹ËùÓÐ92ÖÖ¾úÖê¡£¿¨µÏ¸ñ³ÌåÏÖ£¬ÕâÊÇÒ»ÏîºÜÊÇÁîÈËÐ˷ܵķ¢Ã÷£¬ÌṩÁËÒ»ÖÖȫеÄÒªÁìÀ´¶Ô¿¹Ï¸¾ú¡£Õâ¸ö¡°ÖØ´óÍ»ÆÆ¡±½«×ÊÖú¿ÆÑ§¼Ò¸üºÃµØÃ÷ȷÿÄêÔì³ÉÊý°ÙÍòÓ¤¶ùéæÃüÒÔ¼°Ðí¶àÍíÄêÈË»¼²¡ºÍéæÃüµÄ·ÎÑ׺ÍÄÔĤÑ×ÕâÁ½¸ö×ï¿ý×ï¿ý¡£ £¨ÈªÔ´£º¿Æ¼¼ÈÕ±¨ Áõϼ£©
¡¾µãÆÀ¡¿
¡¡¡¡¸Ã·¢Ã÷¼ÓÉîÁ˹ØÓÚÈËÌå×ÔÉíÃâÒßϵͳ×÷ÓûúÖÆµÄÃ÷È·£¬»òÐíÓÐÖúÓÚ½â¾öÏÖ´úÒ½Ñ§ÃæÁٵĿ¹ÉúËØÄæ¾³¡£
¡¾ÔÎÄժ¼¡¿PLoS Pathog 6(11): e1001191. doi:10.1371/journal.ppat.1001191
Pneumolysin Activates the NLRP3 Inflammasome and Promotes Proinflammatory Cytokines Independently of TLR4
McNeela EA, Burke Á, Neill DR, Baxter C, Fernandes VE, et al.
Pneumolysin (PLY) is a key Streptococcus pneumoniae virulence factor and potential candidate for inclusion in pneumococcal subunit vaccines. Dendritic cells (DC) play a key role in the initiation and instruction of adaptive immunity, but the effects of PLY on DC have not been widely investigated. Endotoxin-free PLY enhanced costimulatory molecule expression on DC but did not induce cytokine secretion. These effects have functional significance as adoptive transfer of DC exposed to PLY and antigen resulted in stronger antigen-specific T cell proliferation than transfer of DC exposed to antigen alone. PLY synergized with TLR agonists to enhance secretion of the proinflammatory cytokines IL-12, IL-23, IL-6, IL-1¦Â, IL-1¦Á and TNF-¦Á by DC and enhanced cytokines including IL-17A and IFN-¦Ã by splenocytes. PLY-induced DC maturation and cytokine secretion by DC and splenocytes was TLR4-independent. Both IL-17A and IFN-¦Ã are required for protective immunity to pneumococcal infection and intranasal infection of mice with PLY-deficient pneumococci induced significantly less IFN-¦Ã and IL-17A in the lungs compared to infection with wild-type bacteria. IL-1¦Â plays a key role in promoting IL-17A and was previously shown to mediate protection against pneumococcal infection. The enhancement of IL-1¦Â secretion by whole live S. pneumoniae and by PLY in DC required NLRP3, identifying PLY as a novel NLRP3 inflammasome activator. Furthermore, NLRP3 was required for protective immunity against respiratory infection with S. pneumoniae. These results add significantly to our understanding of the interactions between PLY and the immune system.
5. FTO»ùÒòÌ«¹ý»îÔ¾¿Éµ¼Ö·ÊÅÖ
¡¾ÕªÒª¡¿
¡¡¡¡Ó¢¹úÅ£½ò´óѧ11ÔÂ15ÈÕÐû²¼µÄÐÂÎŹ«±¨Ö¸³ö£¬¸ÃУÑо¿Ö°Ô±ÕÒµ½ÁËFTO»ùÒò»áµ¼Ö·ÊÅÖµÄÓÐÁ¦Ö¤¾Ý£¬³ÆFTO»ùÒòÌ«¹ý»îÔ¾»áÔì³ÉÒûʳ¹ýÁ¿£¬´Ó¶øµ¼Ö·ÊÅÖ¡£Ïà¹ØÐ§¹û½ÒÏþÔÚ×î½üÒ»ÆÚ¡¶×ÔÈ»¡ªÒÅ´«Ñ§¡·ÔÓÖ¾ÉÏ¡£FTO»ùÒòÒ²³Æ·ÊÅÖ»ùÒò£¬ÊÇÒ»ÖÖÓë·ÊÅÖÏà¹ØµÄµÈλ»ùÒò¡£ÔçÔÚ2007Ä꣬һ¸ö°üÀ¨Å£½ò´óѧ¿ÆÑ§¼ÒÔÚÄڵĹú¼ÊÑо¿Ð¡×éͨ¹ý´óÐÍÈ«»ùÒò×éÑо¿·¢Ã÷£¬FTO»ùÒò±äÒìÓë·ÊÅÖÓйء£Ð¯´øÁ½¸öFTO»ùÒò±äÒ츱±¾µÄÈË£¬Æäƽ¾ùÌåÖØ±ÈÓµÓÐÕý³£¸±±¾µÄÈËÖØ3¹«½ï¡£¶øÔÚÅ·ÖÞѪͳ°×ÈËÖУ¬Ô¼ÄªÓÐ16%µÄÈËЯ´øÁ½¸öFTO»ùÒò±äÒ츱±¾¡£´Ë´ÎÅ£½ò´óѧºÍÓ¢¹úҽѧÀíÊ»áµÄºÏ×÷Ñо¿ÖУ¬Ñо¿Ö°Ô±Ï£ÍûÄÜÈ·¶¨ÊÇ·ñ¾ÍÊÇFTO»ùÒò×Ô¼ºÔ˶¯µÄ²î±ðµ¼ÖÂÁË·ÊÅÖ¡£ÔÚʵÑéÖУ¬Ñо¿Ö°Ô±ÅàÓý³ö¾ßÓжàÓàFTO»ùÒò¸±±¾µÄСÊó£¬ËûÃÇ·¢Ã÷£¬ÕâЩСÊóËäȻҲºÜ¿µ½¡£¬µ«ÓëÆäËüÕý³£Ð¡ÊóÏà±È£¬ËüÃǵÄʳÓû¸üÇ¿£¬¸üÒ×Òûʳ¹ýÁ¿£¬ÌåÐÍÒ²¸ü·Ê˶¡£ÄÇЩÓÐÁ½¸öFTO»ùÒò¸±±¾µÄ´ÆÐÔСÊó£¬×ÝȻʳÆ×ÓëÆäËüÕý³£´ÆÐÔСÊóÏàͬ£¬ÆäÔÚ20ÖܺóµÄÌåÖØÒ²±ÈºóÕßÖØ22%£»µ«¹ØÓÚÐÛÐÔСÊó¶øÑÔ£¬ÕâÖÖÌåÖØ²î±ðÔòԼĪÔÚ10%×óÓÒ¡£
¡¡¡¡¸ÃÏîÑо¿µÄÏòµ¼Õß¡¢Å£½ò´óѧµÄ¸¥ÀÊÎ÷˹¡¤°¢Ê²¿ËÀÍ·òÌØ½ÌÊÚÌåÏÖ£¬¸ÃʵÑéÅú×¢£¬FTO»ùÒòÊÇÓë·ÊÅÖÏà¹ØµÄÖ÷Òª»ùÒò£¬ÕýÊÇFTO»ùÒòÌ«¹ý»îÔ¾£¬²Å»áÔì³ÉСÊóÒûʳ̫¹ý£¬´Ó¶øµ¼ÖÂÌåÖØ´ó·ùÔöÌí¡£Ñо¿ÂÛÎÄ×÷ÕßÖ®Ò»¡¢Å£½ò´óѧµÄ¿ËÀï˹¡¤ÇðÆæÔò³Æ£¬ÕâÊÇÑо¿Ö°Ô±µÚÒ»´ÎÕÒµ½ÁîÈËÐÅ·þµÄÖ¤¾Ý֤ʵFTO»ùÒòÄܹ»µ¼Ö·ÊÅÖ¡£¶øÏÂÒ»²½£¬ËûÃÇÒªÖÂÁ¦ÓÚÑо¿Ïà¹Ø»úÖÆ£¬Ò»µ©ÏàʶÁËFTO»ùÒòµ¼Ö·ÊÅֵĻúÖÆ£¬¾Í¿ÉÒÔ¿ª·¢³öÓÐÓõķÊÅÖÖÎÁÆÒ©Îï¡£ÏàÐÅÕâÖÖÄܹ»ÒÖÖÆ»ùÒòÔ˶¯µÄÒ©Îォ¾ßÓкܺõÄÓ¦ÓÃÔ¶¾°¡££¨ÈªÔ´£º¿Æ¼¼ÈÕ±¨ Áõº£Ó¢£©
¡¾µãÆÀ¡¿
¡¡¡¡µÚÒ»´ÎÓÐÖ±½ÓÖ¤¾ÝÅú×¢FTO»ùÒòÌ«¹ý»îÔ¾»áÔì³ÉСÊóÒûʳ¹ýÁ¿£¬´Ó¶øµ¼Ö·ÊÅÖ¡£ÕâÒ»·¢Ã÷ÓÐÖúÓÚ¶Ô·ÊÅÖ¼°ÆäÏà¹Ø´úл¼²²¡µÄÉîÈëÏàʶ¡£
¡¾ÔÎÄժ¼¡¿Nature Genetics DOI: doi:10.1038/ng.713
Overexpression of Fto leads to increased food intake and results in obesity
Chris Church, Lee Moir, Fiona McMurray, et al.
Genome-wide association studies have identified SNPs within FTO, the human fat mass and obesity¨Cassociated gene, that are strongly associated with obesity. Individuals homozygous for the at-risk rs9939609 A allele weigh, on average, ~3 kg more than individuals with the low-risk T allele. Mice that lack FTO function and/or Fto expression display increased energy expenditure and a lean phenotype. We show here that ubiquitous overexpression of Fto leads to a dose-dependent increase in body and fat mass, irrespective of whether mice are fed a standard or a high-fat diet. Our results suggest that increased body mass results primarily from increased food intake. Mice with increased Fto expression on a high-fat diet develop glucose intolerance. This study provides the first direct evidence that increased Fto expression causes obesity in mice.
6. άÉúËØDȱ·¦¿Éµ¼Ö°×Ѫ²¡¶ñ»¯
¡¾ÕªÒª¡¿
¡¡¡¡ÃÀ¹úÒ»ÏîÐÂÑо¿·¢Ã÷£¬»úÌåÄÚάÉúËØDˮƽÓë°×Ѫ²¡Ö®¼ä±£´æÏ¸ÃÜÁªÏµ£¬Î¬ÉúËØDȱ·¦¿ÉÄÜ»áÒýÆð²¡Çé¶ñ»¯£¬Î¬ÉúËØDˮƽÕý³£Ôò»áÑÓÉ첡ÈË´æ»îʱ¼ä¡£ÕâÏîÑо¿ÓÉÃÀ¹ú÷°ÂÕïËùºÍ°¬°ÂÍß´óѧµÄÑо¿Ö°Ô±ÅäºÏÍê³É£¬Ñо¿Éæ¼°390ÃûÂýÐÔÁܰÍϸ°û°×Ѫ²¡»¼Õߣ¬ÆäÖÐ30%µÄÈËÔÚ¸Õ»¼²¡Ê±±»·¢Ã÷άÉúËØDȱ·¦£¨¼´Ã¿ºÁÉýѪҺÉÙÓÚ25ºÁ΢¿Ë£©¡£ÔÚÒÔºó3ÄêµÄ¸ú×ÙÊÓ²ìʱ´ú£¬È±·¦Î¬ÉúËØDµÄ°×Ѫ²¡»¼ÕߵIJ¡Çé¶ñ»¯ºÍ½ÓÊÜ»¯ÁƵļ¸ÂÊÒª±ÈÆäËû²¡È˸ß66%£¬éæÃüΣº¦ÔòÒª¸ßÁ½±¶ÒÔÉÏ¡£Ñо¿»¹·¢Ã÷£¬Ìá¸ß°×Ѫ²¡»¼ÕßµÄάÉúËØDˮƽ¿ÉÑÓÉìËûÃǵĴæ»îʱ¼ä£¬ÕâÒ»½áÂÛ²»ÊÜÓë°×Ѫ²¡Éú³¤ÓйØÒòËØµÄÓ°Ïì¡£Ñо¿Ö°Ô±Ëµ£¬ËûÃǶÔÁíÒ»×é°×Ѫ²¡»¼Õß¾ÙÐÐÁËΪÆÚ10ÄêµÄÑо¿£¬µÃ³öÁËͬÑù½áÂÛ¡£Ñо¿Ö°Ô±Ö¸³ö£¬ÕâÒ»·¢Ã÷½«ÓÐÖúÓÚ¸üÓÐÓõØÖÎÁư×Ѫ²¡£¬ÓÉÓÚ²¡ÈË¿ÉÒÔÆ¾Ö¤ÐèҪʵʱÔö²¹Î¬ÉúËØD£¬ÕâÒ»ÒªÁì¼ÈdzÒ׿ÉÐУ¬ÓÖ²»»á±¬·¢¸±×÷Óá£Ñо¿Ö°Ô±Ëµ£¬ËûÃÇÍýÏëÔÚÁíÒ»ÏîÑо¿Öе÷Àí»¼ÕßµÄάÉúËØDˮƽ£¬¿´ÊÇ·ñÄÜÒԴ˸ÄÉÆ²¡È˵ÄÔ¤ºó¡£Ñо¿±¨¸æ¿¯µÇÔÚÐÂÒ»ÆÚÃÀ¹úѧÊõÆÚ¿¯¡¶ÑªÒº¡·ÔÓÖ¾ÉÏ¡££¨ÈªÔ´£ºÐ»ªÍø ¸ßÔ£©
¡¾µãÆÀ¡¿
¡¡¡¡ÌåÄÚάÉúËØDˮƽÓë°×Ѫ²¡Ö®¼ä±£´æÏ¸ÃÜÁªÏµ£¬Åú×¢ÎúÓªÑø²»Á¼Óë°©Ö¢±¬·¢Ö®¼äÒ»¶¨µÄ¹ØÁªÐÔ¡£
¡¾ÔÎÄժ¼¡¿Blood; DOI 10.1182/blood-2010-07-295683.
Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia (CLL)
Tait D. Shanafelt,, Matthew T. Drake, Matthew J. Maurer, et al.
Vitamin D insufficiency is common globally with low levels linked to higher cancer incidence. Although vitamin D insufficiency is related to inferior prognosis in some cancers, no data exist for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). We evaluated the relationship of 25(OH)D serum levels with time-to-treatment(TTT) and overall survival(OS) in newly diagnosed CLL patients participating in a prospective cohort study(discovery cohort) and a separate cohort of previously untreated patients participating in an observational study(confirmation cohort). Of 390 CLL patients in the discovery cohort, 119(30.5%) were 25(OH)D insufficient. After median follow-up of 3 years, TTT(hazard ratio[HR]=1.66; p=0.005) and OS(HR=2.39; p=0.01) were shorter for 25(OH)D insufficient patients. In the validation cohort, 61 of 153 patients(39.9%) were 25(OH)D insufficient. After median follow-up of 9.9 years, TTT(HR=1.59; p=0.05) and OS(HR 1.63; p=0.06) were again shorter for 25(OH)D insufficient patients. On pooled multivariable analysis of patients in both cohorts adjusting for age, sex, stage, CD38, ZAP-70, IGHV, CD49d, and FISH, 25(OH)D insufficiency remained an independent predictor of TTT(HR=1.47; p=0.008), although the association with OS was not significant(HR=1.47; p=0.07). Vitamin D insufficiency is associated with inferior TTT and OS in CLL patients. Whether normalizing vitamin D levels in deficient CLL patients would improve outcome merits clinical testing.